Nelarabine – A New Age in the Management of Lymphoid Malignancies


https://doi.org/10.4081/hmr.v2i13.486
Vol. 2 No. 13: It’s time to take care of T-Cell Lymphomas Bologna, Italy, 22-24 October 2006
Published: June 10, 2009
Abstract Views: 194
PDF: 211
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Nelarabine is the 6-methoxy prodrug of 9-b-D-arabinofuranosylguanine (ara-G)11 Nelarabine is a substrate for adenosine deaminase, which cleaves the methoxy group to form ara-G (Figure 1). Ara-G is taken up by the cell and is then triphosphorylated by two enzymes, deoxycytidine kinase and deoxyguanosine kinase2 (Figure 2). Ara-G triphosphate (ara-GTP) competes with deoxy-GTP in malignant cells for incorporation into DNA.3 Once incorporation occurs, ara-GTP results in chain termination and apoptosis.2 Ara-GTP accumulates to a greater extent in T-cells compared with B-cells. This may explain Nelarabine’s greater activity in T-cell malignancies than B-lymphocyte malignancies. Elimination half-life of ara-GTP is longer in leukemic T-cells than in leukemic B-cells.4

Supporting Agencies


Keating, M. (2009). Nelarabine – A New Age in the Management of Lymphoid Malignancies. Hematology Meeting Reports (formerly Haematologica Reports), 2(13). https://doi.org/10.4081/hmr.v2i13.486
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC